Cantor Fitzgerald reiterated an overweight rating on BioPharma shares, reducing the target price and setting a buy rating.
4 reports, 1 independent
Updated Aug 12
Gone quiet
- Reports
- 4
- Developments
- 1
- Repetition
- 75%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Cantor Fitzgerald reiterated an overweight rating on BioPharma shares, reducing the target price and setting a buy rating.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Cantor Fitzgerald
American financial services company
-
BioPharma
company in Jílové u Prahy, Czech Republic
Related events
- Cantor Fitzgerald reiterated an overweight rating on CleanSpark shares.
- Cantor Fitzgerald reiterated an Overweight rating on Amazon stock.
- Cantor Fitzgerald and Citigroup issued rating updates, while MarketBeat reported research notes on Quince Therapeutics.
- Cantor Fitzgerald reaffirmed an overweight rating on the shares of Gorilla Technology Group Inc. on August 31, 2026.
- Avalo Therapeutics received multiple rating changes and analyst coverage from firms including Cantor Fitzgerald, Bank of America, and Weiss Ratings.